Matthew L. Posard
CIK: 0001543792
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Oct 1, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct1.1K shares at avg. $109.57$121K - Oct 1, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct100 shares at avg. $110.04$11K - Oct 1, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct730 shares at avg. $107.17$78K - Oct 1, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct3.3K shares at avg. $108.45$358K - Sep 16, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct8.9K shares at avg. $108.04$961K - Sep 16, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct4K shares at avg. $108.99$436K - Sep 16, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct3.1K shares at avg. $106.13$329K - Sep 16, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct3K shares at avg. $106.83$320K - Jun 18, 2026NAUT
Nautilus Biotechnology, Inc.
Award(A)DirectStock Option (Right to Buy)
45K shares- - May 5, 2026HALO
HALOZYME THERAPEUTICS, INC.
Award(A)Direct3.8K shares- - Jun 23, 2025NAUT
Nautilus Biotechnology, Inc.
Award(A)DirectStock Option (Right to Buy)
45K shares- - May 1, 2025HALO
HALOZYME THERAPEUTICS, INC.
Award(A)Direct4.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 |  HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 1,100 | $109.57 | $120,526 | Direct |
| Oct 1, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 100 | $110.04 | $11,004 | Direct |
| Oct 1, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 730 | $107.17 | $78,233 | Direct |
| Oct 1, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 3,300 | $108.45 | $357,898 | Direct |
| Sep 16, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 8,896 | $108.04 | $961,124 | Direct |
| Sep 16, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 4,000 | $108.99 | $435,964 | Direct |
| Sep 16, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 3,100 | $106.13 | $329,009 | Direct |
| Sep 16, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 3,000 | $106.83 | $320,484 | Direct |
| Jun 18, 2026 |  NAUT Nautilus Biotechnology, Inc. | Award(A) Stock Option (Right to Buy) | 45,000 | - | - | Direct |
| May 5, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Award(A) | 3,796 | - | $0 | Direct |
| Jun 23, 2025 | NAUT Nautilus Biotechnology, Inc. | Award(A) Stock Option (Right to Buy) | 45,000 | - | - | Direct |
| May 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Award(A) | 4,165 | - | - | Direct |
1-12 of 12 transactions
About Posard Matthew L.
Posard Matthew L. (SEC CIK 0001543792) files insider reports with the SEC as Director of HALOZYME THERAPEUTICS, INC. (HALO) and Director of Nautilus Biotechnology, Inc. (NAUT).
Signal8 holds 6 ownership filings by Posard Matthew L., all Form 4s, filed between May 2, 2025 and Oct 2, 2026. Those filings report 12 transactions, from May 1, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Posard Matthew L.'s filings is in SAN DIEGO, CA.
Recent filings by Posard Matthew L.
- Oct 1, 2026: Open-market sales of HALO shares (4 lines, Form 4, code S).
- Sep 16, 2026: Open-market sales of HALO shares (4 lines, Form 4, code S).
- Jun 18, 2026: Grant or award of NAUT derivative securities (Form 4, code A).
- May 5, 2026: Grant or award of HALO shares (Form 4, code A).
- Jun 23, 2025: Grant or award of NAUT derivative securities (Form 4, code A).
Other insiders filing for HALOZYME THERAPEUTICS, INC. (HALO)
- Torley Helen, PRESIDENT AND CEO
- Connaughton Bernadette, Director
- Daly James M, Director
- Appelhans Dannielle, Director
- RAMSAY DAVID A, EVP, PRESIDENT, DRUG DELIVERY
- Snellgrove Darren, SVP, Chief Financial Officer